Form 4 Filing for BridgeBio Pharma, Inc. - Insider Transaction

Charles J. Homcy, a director at BridgeBio Pharma, Inc. (BBIO), reported a transaction on June 22, 2026. He acquired 3,990 shares of Common Stock and was granted 5,277 Stock Options (Right to Buy). These RSUs vest on June 22, 2027, contingent upon his continued service. The stock option also vests on the same date, subject to continued service. The exercise price for the option is $68.92. Following these transactions, Homcy directly owns 919,876 shares of Common Stock and 5,277 stock options.